| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695084 | Gynecologic Oncology | 2017 | 5 Pages |
Abstract
- The optimal clinical use of PARP inhibitors-as treatment or maintenance-is unclear.
- Progression-free survival alone may be insufficient to support use as maintenance.
- Clinicians and patients must consider various factors in each setting.
- Potential clinical benefit must be balanced with symptoms from disease or treatment.
- Patient perceptions, such as quality of life, should be considered in both settings.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Whitney S. Graybill, Bhavana Pothuri, Dana M. Chase, Bradley J. Monk,